GEL RÉVERSIBLE POUR ADMINISTRATION DE MÉDICAMENT NON ORALE, COMPRENANT UNE VÉSICULE MULTINANODOMAINE NON CONCENTRIQUE ET UN NANOLIPOSOME, ET COMPOSITION POUR ADMINISTRATION DE MÉDICAMENT LE COMPRENANT
The present invention provides a reversible gel for non-oral drug delivery, comprising: a non-concentric multi-nanodomain vesicle including two or more liposomes contiguously connected to each other, and an outer wall surrounding the two or more liposomes； and a nanoliposome, wherein the non-concentric multi-nanodomain vesicle consists of an organic phase containing a hydrophobic drug, and an aqueous phase containing a hydrophilic drug, and is negatively charged, and the nanoliposome is positively charged. According to the present invention, the reversible gel for non-oral drug delivery can increase the encapsulation efficiency of various hydrophobic and hydrophilic drugs, and can be easily injected with a single syringe, and once injected, forms a gel in the body. Due to the aforesaid characteristics, the reversible gel for non-oral drug delivery can overcome the limitation of a vesicle- or liposome-based drug delivery system that, when used alone, migrates to surrounding tissues and renders a sustained-release behavior difficult to induce, and can be used in surgery sites or the like. Moreover, according to the present invention, the reversible gel for non-oral drug delivery loaded with a drug that regulates the functions of cancer cells and various immunocytes, can dramatically increase the efficacy of cancer immunotherapies when used in combination with immune checkpoint inhibitors.La présente invention concerne un gel réversible destiné à l'administration de médicament non orale, comprenant : une vésicule multinanodomaine non concentrique comprenant au moins deux liposomes reliés de manière contiguë l'un à l'autre, et une paroi externe entourant les au moins deux liposomes ； et un nanoliposome. La vésicule multinanodomaine non concentrique est constituée d'une phase organique contenant un médicament hydrophobe, et une phase aqueuse contenant un médicament hydrophile, et est chargée négativement, et le nanoliposome est chargé positivement. Selon la présente inve
